Who
Pol F. Boudes
Director
Company insider
Files Form 4 as: Director, Protalix BioTherapeutics, Inc. (DE); Chief Medical Officer, Galectin Therapeutics; Chief Medical Officer, CymaBay Therapeutics; Chief Medical Officer, Amicus Therapeutics.
In numbers
- Trades disclosed
- 32
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 3 Feb 2009
- Last trade
- 3 Sep 2026
- Last filed
- 4 Sep 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Sep 2026filed 4 Sep 2026 | PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · Biotechnology | SEC FORM 4 Code A | —17,000 at $0.00 | filing |
| 3 Sep 2026filed 4 Sep 2026 | PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · Biotechnology | SEC FORM 4 Code A | —8,500 at $0.00 | filing |
| 3 Sep 2026filed 4 Sep 2026 | PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · Biotechnology | SEC FORM 4 Code A | —17,000 at $0.00 | filing |
| 3 Sep 2026filed 4 Sep 2026 | PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · Biotechnology | SEC FORM 4 Code A | —8,500 at $0.00 | filing |
| 3 Sep 2025filed 4 Sep 2025 | PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 3 Sep 2025filed 4 Sep 2025 | PLX Protalix BioTherapeutics, Inc. (DE)Biotechnology | SEC FORM 4 Code A | —7,500 | filing |
| 24 Jan 2024filed 7 Feb 2024 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 24 Jan 2024filed 7 Feb 2024 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 29 Sep 2023filed 3 Oct 2023 | PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · Biotechnology | SEC FORM 4 Code A | —61,676 at $0.00 | filing |
| 26 Jan 2023filed 30 Jan 2023 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 7 Sep 2022filed 9 Sep 2022 | PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 24 Jan 2022filed 25 Jan 2022 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 25 Mar 2021filed 29 Mar 2021 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 25 Mar 2021filed 29 Mar 2021 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 12 Mar 2020filed 16 Mar 2020 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 20 Jan 2020filed 22 Jan 2020 | PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 29 Jan 2019filed 31 Jan 2019 | CymaBay Therapeuticsoption or derivative | SEC FORM 4 Code A | —138,312 at $0.00 | filing |
| 24 Jan 2018filed 26 Jan 2018 | CymaBay Therapeuticsoption or derivative | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 19 Jan 2017filed 23 Jan 2017 | CymaBay Therapeuticsoption or derivative | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 4 Jan 2017filed 6 Jan 2017 | CymaBay Therapeuticsoption or derivative | SEC FORM 4 Code A | —21,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.